ArticleThoracic cancer2022

Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs.

Peng Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.